Measles and rubella in the World Health Organization European region: diversity creates challenges.
Since 1984, the World Health Organization (WHO) European Region has had targets for reducing the burden of a number of communicable diseases. While some countries have already met the targets for interrupting indigenous measles transmission and for reducing the incidence of congenital rubella syndrome to <1 case per 100,000 births, most have not. The cultural and economic diversity of the region present a number of challenges that must be overcome before the regional targets are met. These include social factors, political will, economic costs associated with supplementary campaigns, and more effective communication with health professionals and the public on the benefits and risks associated with immunization. Most WHO European Region member states are expected to use combined measles-mumps-rubella vaccine within the next 5 years. Consultation within the region is occurring on a strategic plan to meet the targets by 2010.
Spika
John S
JS
World Health Organization Regional Office for Europe, Copenhagen, Denmark. jsp@who.dk
Wassilak
Steven
S
Pebody
Richard
R
Lipskaya
Galina
G
Deshevoi
Sergei
S
Guris
Dalya
D
Emiroglu
Nedret
N
D005060:Europe / Q000453:epidemiology; D006801:Humans; D017589:Immunization Programs / Q000379:methods*; D015994:Incidence; D007223:Infant; D008457:Measles / Q000453:epidemiology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage*; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage*; D011159:Population Surveillance; D012409:Rubella / Q000453:epidemiology / Q000517:prevention & control*; D012410:Rubella Syndrome, Congenital / Q000517:prevention & control
D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine